Gary V. Doern
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gary V. Doern has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Angela B. Brueggemann
Nuffield Department of Population Health, University of Oxford, Oxford, UK
7 shared publications Sandra S. Richter
Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, Iowa 52242-1009, USA
6 shared publications- Holly K. Huynh
<!--label omitted: 1-->Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa
5 shared publications - Paul Richard Rhomberg
JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
5 shared publications Susan E. Beekmann
Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, Iowa
4 shared publicationsErik L. Munson
Division of Medical Microbiology, Department of Pathology, University of Iowa, Carver College of Medicine, Iowa City, IA 52242, USA
3 shared publications
Latest Publications
- 1 January 2009
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 47 (1) , 275-277
Lactobacillus delbrueckii as the Cause of Urinary Tract Infection
Lactobacilli are part of the normal bacterial flora of the vagina and are typically considered contaminants when cultured from urine specimens of female patients. Here we describe the case of a female patient with chronic pyuria and urinary tract symptoms in which Lactobacillus delbrueckii was determined to be the causative microorganism.
- 1 January 2009
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 47 (1) , 275-277
Lactobacillus delbrueckii as the Cause of Urinary Tract Infection
Lactobacilli are part of the normal bacterial flora of the vagina and are typically considered contaminants when cultured from urine specimens of female patients. Here we describe the case of a female patient with chronic pyuria and urinary tract symptoms in which Lactobacillus delbrueckii was determined to be the causative microorganism.
- 1 July 2008
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 46 (7) , 2184-2188
Accuracy of Phenotypic Methods for Identification of Streptococcus pneumoniae Isolates Included in Surveillance Programs
Similarities between Streptococcus pneumoniae and viridans group streptococci may result in misidentification of these organisms. In surveillance programs which assess antimicrobial resistance rates among respiratory tract pathogens, such identification errors could lead to overestimates of pneumococcal resistance rates. DNA probe analysis (Gen-Probe, San Diego, CA), the bile solubility test, optochin susceptibility, colony morphology, and the capsular swelling reaction with Omni serum (Staten Serum Institut, Copenhagen, Denmark) were used to characterize 1,733 organisms provisionally identified as S. pneumoniae in a 2004 to 2005 antimicrobial resistance surveillance program. These organisms were obtained in 41 U.S. medical centers. Among these, 1,647 (95%) were determined to be S. pneumoniae by DNA probe. Elimination of those isolates found not to be S. pneumoniae resulted in 1 to 2% decreases in resistance rate estimates with penicillin, erythromycin, tetracycline, and trimethoprim-sulfamethoxazole. With AccuProbe as a reference standard, the sensitivities and specificities of each phenotypic method for the identification of S. pneumoniae were, respectively, 98.8% and 82.6% for bile solubility, 99.3% and 74.4% for the capsular swelling reaction with Omni serum, and 87.9% and 59.3% for optochin susceptibility. Colony morphology was of limited value, as 391 (23.7%) isolates lacked the typical button or mucoid colony appearance of S. pneumoniae .
- 1 July 2008
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 46 (7) , 2184-2188
Accuracy of Phenotypic Methods for Identification of Streptococcus pneumoniae Isolates Included in Surveillance Programs
Similarities between Streptococcus pneumoniae and viridans group streptococci may result in misidentification of these organisms. In surveillance programs which assess antimicrobial resistance rates among respiratory tract pathogens, such identification errors could lead to overestimates of pneumococcal resistance rates. DNA probe analysis (Gen-Probe, San Diego, CA), the bile solubility test, optochin susceptibility, colony morphology, and the capsular swelling reaction with Omni serum (Staten Serum Institut, Copenhagen, Denmark) were used to characterize 1,733 organisms provisionally identified as S. pneumoniae in a 2004 to 2005 antimicrobial resistance surveillance program. These organisms were obtained in 41 U.S. medical centers. Among these, 1,647 (95%) were determined to be S. pneumoniae by DNA probe. Elimination of those isolates found not to be S. pneumoniae resulted in 1 to 2% decreases in resistance rate estimates with penicillin, erythromycin, tetracycline, and trimethoprim-sulfamethoxazole. With AccuProbe as a reference standard, the sensitivities and specificities of each phenotypic method for the identification of S. pneumoniae were, respectively, 98.8% and 82.6% for bile solubility, 99.3% and 74.4% for the capsular swelling reaction with Omni serum, and 87.9% and 59.3% for optochin susceptibility. Colony morphology was of limited value, as 391 (23.7%) isolates lacked the typical button or mucoid colony appearance of S. pneumoniae .
- 1 April 2008
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 46 (4) , 1381-1385
Timing of Specimen Collection for Blood Cultures from Febrile Patients with Bacteremia
Bloodstream infections are an important cause of morbidity and mortality. Physician orders for blood cultures often specify that blood specimens be collected at or around the time of a temperature elevation, presumably as a means of enhancing the likelihood of detecting significant bacteremia. In a multicenter study, which utilized retrospective patient chart reviews as a means of collecting data, we evaluated the timing of blood culture collection in relation to temperature elevations in 1,436 patients with bacteremia and fungemia. The likelihood of documenting bloodstream infections was not significantly enhanced by collecting blood specimens for culture at the time that patients experienced temperature spikes. A subset analysis based on patient age, gender, white blood cell count and specific cause of bacteremia generally also failed to reveal any associations.
- 1 April 2008
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 46 (4) , 1381-1385
Timing of Specimen Collection for Blood Cultures from Febrile Patients with Bacteremia
Bloodstream infections are an important cause of morbidity and mortality. Physician orders for blood cultures often specify that blood specimens be collected at or around the time of a temperature elevation, presumably as a means of enhancing the likelihood of detecting significant bacteremia. In a multicenter study, which utilized retrospective patient chart reviews as a means of collecting data, we evaluated the timing of blood culture collection in relation to temperature elevations in 1,436 patients with bacteremia and fungemia. The likelihood of documenting bloodstream infections was not significantly enhanced by collecting blood specimens for culture at the time that patients experienced temperature spikes. A subset analysis based on patient age, gender, white blood cell count and specific cause of bacteremia generally also failed to reveal any associations.
- 1 December 2007
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 45 (12) , 4051-4053
Comparison of Three Commercial Test Systems for Biotyping Haemophilus influenzae and Haemophilus parainfluenzae
The biotypes of Haemophilus influenzae and Haemophilus parainfluenzae isolates were determined with three commercially available biochemical test kits: the IDS RapID NH system, the Neisseria-Haemophilus identification test (NHI card), and the API NH strip. The API NH strip performed best, correctly classifying the biotypes of 371 of 380 (97.6%) different challenge strains.
- 1 December 2007
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 45 (12) , 4051-4053
Comparison of Three Commercial Test Systems for Biotyping Haemophilus influenzae and Haemophilus parainfluenzae
The biotypes of Haemophilus influenzae and Haemophilus parainfluenzae isolates were determined with three commercially available biochemical test kits: the IDS RapID NH system, the Neisseria-Haemophilus identification test (NHI card), and the API NH strip. The API NH strip performed best, correctly classifying the biotypes of 371 of 380 (97.6%) different challenge strains.
- Open Access
- 1 October 2007
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 6 (1) , 11
A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004
Background: Increasing nosocomial pathogen resistance to available antimicrobial agents is of growing concern. While higher MICs can diminish antimicrobial effectiveness, dose adjustments often mitigate this effect. This study's objective was to ascertain whether MICs among major pathogens in the ICU to several commonly used agents have increased enough to significantly impact their ability to achieve bactericidal effect. Methods: Cefepime, ceftriaxone, imipenem and piperacillin-tazobactam MICs were determined with 74,394 Gram-negative bacilli obtained from ICU patients with various infections in the US between 1993 and 2004. Results were grouped into four 3-year periods. The predicted cumulative fraction of response (CFR) was estimated based on patient-derived pharmacokinetic values and Monte Carlo simulation. Trends in CFR over the four study periods were assessed using the Cochran-Armitage test. The primary analysis included all organisms combined; Pseudomonas aeruginosa and Acinetobacter species were also evaluated individually. Results: In the primary analysis, imipenem 500 mg q6h showed CFRs from 87% to 90% across all four study periods, with a trend toward slightly improved bactericidal target attainment (p < 0.01). CFRs for cefepime 2 g q12h and piperacillin-tazobactam 4.5 g q6h both declined by 2% (p < 0.01 and p < 0.05, respectively), reflecting upward shifts in the underlying MIC distributions. Ceftriaxone had P. aeruginosa, significant declines in CFR were seen for (range, p-value): imipenem 1 g q8h (82%–79%, p < 0.01), cefepime 1 g q12h (70%–67%, p < 0.01), cefepime 2 g q12h (84%–82%, p < 0.05), piperacillin-tazobactam 3.375 g q6h (76%–73%, p < 0.01), piperacillin-tazobactam 4.5 g q8h (71%–68%, p < 0.01), and piperacillin-tazobactam 4.5 g q6h (80%–77%, p < .01). Against Acinetobacter spp., all regimens of imipenem, cefepime and piperacillin-tazobactam showed significant declines in CFR over time (p < 0.01). Conclusion: Our observations suggest that as a result of increasing antimicrobial resistance among ICU pathogens in the US, drug effectiveness, assessed as a function of individual agents' ability to attain pharmacodynamic targets, has declined, especially with P. aeruginosa and Acinetobacter spp. Cefepime 2 g q8h and imipenem were the most potent agents against these species, respectively. More aggressive dosing of all of the agents characterized could preserve their clinical utility, but this must be balanced with safety and tolerability issues by the physician.
- 1 October 2007
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 6 (1) , 11
Open AccessA pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004
Background: Increasing nosocomial pathogen resistance to available antimicrobial agents is of growing concern. While higher MICs can diminish antimicrobial effectiveness, dose adjustments often mitigate this effect. This study's objective was to ascertain whether MICs among major pathogens in the ICU to several commonly used agents have increased enough to significantly impact their ability to achieve bactericidal effect. Methods: Cefepime, ceftriaxone, imipenem and piperacillin-tazobactam MICs were determined with 74,394 Gram-negative bacilli obtained from ICU patients with various infections in the US between 1993 and 2004. Results were grouped into four 3-year periods. The predicted cumulative fraction of response (CFR) was estimated based on patient-derived pharmacokinetic values and Monte Carlo simulation. Trends in CFR over the four study periods were assessed using the Cochran-Armitage test. The primary analysis included all organisms combined; Pseudomonas aeruginosa and Acinetobacter species were also evaluated individually. Results: In the primary analysis, imipenem 500 mg q6h showed CFRs from 87% to 90% across all four study periods, with a trend toward slightly improved bactericidal target attainment (p < 0.01). CFRs for cefepime 2 g q12h and piperacillin-tazobactam 4.5 g q6h both declined by 2% (p < 0.01 and p < 0.05, respectively), reflecting upward shifts in the underlying MIC distributions. Ceftriaxone had P. aeruginosa, significant declines in CFR were seen for (range, p-value): imipenem 1 g q8h (82%–79%, p < 0.01), cefepime 1 g q12h (70%–67%, p < 0.01), cefepime 2 g q12h (84%–82%, p < 0.05), piperacillin-tazobactam 3.375 g q6h (76%–73%, p < 0.01), piperacillin-tazobactam 4.5 g q8h (71%–68%, p < 0.01), and piperacillin-tazobactam 4.5 g q6h (80%–77%, p < .01). Against Acinetobacter spp., all regimens of imipenem, cefepime and piperacillin-tazobactam showed significant declines in CFR over time (p < 0.01). Conclusion: Our observations suggest that as a result of increasing antimicrobial resistance among ICU pathogens in the US, drug effectiveness, assessed as a function of individual agents' ability to attain pharmacodynamic targets, has declined, especially with P. aeruginosa and Acinetobacter spp. Cefepime 2 g q8h and imipenem were the most potent agents against these species, respectively. More aggressive dosing of all of the agents characterized could preserve their clinical utility, but this must be balanced with safety and tolerability issues by the physician.
- 6 June 2007
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 26 (7) , 485-490
Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae
The study presented here determined the relationship between antimicrobial resistance in Streptococcus pneumoniae and the use of antimicrobial agents in 15 different European countries. Pneumococcal isolates (n = 1974) recovered from patients with community-acquired respiratory tract infections during the winter of 2004–2005 in 15 European countries were characterized. The overall percentages of isolates demonstrating intermediate or complete resistance to penicillin, erythromycin, tetracycline, trimethoprim-sulfamethoxazole (TMP-SMX) and ciprofloxacin were 24, 24.6, 19.8, 26.7 and 2%, respectively, as determined using the broth microdilution MIC method recommended by the Clinical and Laboratory Standards Institute. The overall and mean antimicrobial consumption levels (ACL)—i.e., the defined daily doses per 1,000 inhabitants per day—were obtained from the European Surveillance of Antimicrobial Consumption project for each of the 15 countries for the years 1998–2004. Using linear regression analysis, the mean annual ACL for β-lactams, macrolides, tetracyclines, TMP-SMX and fluoroquinolones in each country was compared to the country-specific resistance rates determined in 2004–2005. The rate of overall antimicrobial use in all 15 European countries was significantly associated with antimicrobial resistance in S. pneumoniae. There was variation among the different antimicrobial classes as drivers of resistance, with β-lactams having the strongest association.
- 6 June 2007
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 26 (7) , 485-490
Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae
The study presented here determined the relationship between antimicrobial resistance in Streptococcus pneumoniae and the use of antimicrobial agents in 15 different European countries. Pneumococcal isolates (n = 1974) recovered from patients with community-acquired respiratory tract infections during the winter of 2004–2005 in 15 European countries were characterized. The overall percentages of isolates demonstrating intermediate or complete resistance to penicillin, erythromycin, tetracycline, trimethoprim-sulfamethoxazole (TMP-SMX) and ciprofloxacin were 24, 24.6, 19.8, 26.7 and 2%, respectively, as determined using the broth microdilution MIC method recommended by the Clinical and Laboratory Standards Institute. The overall and mean antimicrobial consumption levels (ACL)—i.e., the defined daily doses per 1,000 inhabitants per day—were obtained from the European Surveillance of Antimicrobial Consumption project for each of the 15 countries for the years 1998–2004. Using linear regression analysis, the mean annual ACL for β-lactams, macrolides, tetracyclines, TMP-SMX and fluoroquinolones in each country was compared to the country-specific resistance rates determined in 2004–2005. The rate of overall antimicrobial use in all 15 European countries was significantly associated with antimicrobial resistance in S. pneumoniae. There was variation among the different antimicrobial classes as drivers of resistance, with β-lactams having the strongest association.
- 1 November 2006
- Published by Elsevier in Medical Clinics of North America
- Vol. 90 (6) , 1109-1124
Macrolide and Ketolide Resistance with Streptococcus pneumoniae
- 1 November 2006
- Published by Elsevier in Medical Clinics of North America
- Vol. 90 (6) , 1109-1124
Macrolide and Ketolide Resistance with Streptococcus pneumoniae
- 1 October 2006
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 4 (5) , 821-835
Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance
Community-acquired respiratory tract infections (CARTIs) are the most common reason for prescribing antibiotics in the primary care setting. However, over the last decade, the management of CARTIs has become increasingly complicated by the steady increase in prevalence of drug-resistant pathogens responsible for these infections. As a result, significant attention has been directed at understanding the mechanisms of pathogen acquisition of resistance, drivers of resistance and methods for preventing the development of resistance. Data from recent surveillance studies suggest a slowing or decline in resistance rates to agents, such as beta-lactams, macrolides, tetracyclines and folic acid metabolism inhibitors. However, resistance to one antimicrobial family--the fluoroquinolones--while still low, appears to be on the increase. This is of significant concern given the rapid increase in resistance noted with older antibiotics in recent history. While the clinical implications of antibacterial resistance are poorly understood, the overall rates of antimicrobial resistance, as reported in recent surveillance studies, do not correspond to current rates of failure in patients with CARTIs. This disconnection between laboratory-determined resistance and clinical outcome has been termed the in vitro-in vivo paradox and several explanations have been offered to explain this phenomenon. Solving the problem of antimicrobial resistance will be multifactorial. Important factors in this effort include the education of healthcare providers, patients and the general healthcare community regarding the hazards of inappropriate antibiotic use, prevention of infections through vaccination, development of accurate, inexpensive and timely point-of-care diagnostic tests to aid in patient assessment, institution of objective treatment guidelines and use of more potent agents, especially those with a focused spectrum of activity, earlier in the treatment of CARTIs as opposed to reserving them as second-line treatment options. Ultimately, the single-most important factor will be the judicious use of antibiotics, as fewer antibiotic prescriptions lead to fewer antimicrobial-resistant bacteria.
- 1 October 2006
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 4 (5) , 821-835
Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance
Community-acquired respiratory tract infections (CARTIs) are the most common reason for prescribing antibiotics in the primary care setting. However, over the last decade, the management of CARTIs has become increasingly complicated by the steady increase in prevalence of drug-resistant pathogens responsible for these infections. As a result, significant attention has been directed at understanding the mechanisms of pathogen acquisition of resistance, drivers of resistance and methods for preventing the development of resistance. Data from recent surveillance studies suggest a slowing or decline in resistance rates to agents, such as beta-lactams, macrolides, tetracyclines and folic acid metabolism inhibitors. However, resistance to one antimicrobial family--the fluoroquinolones--while still low, appears to be on the increase. This is of significant concern given the rapid increase in resistance noted with older antibiotics in recent history. While the clinical implications of antibacterial resistance are poorly understood, the overall rates of antimicrobial resistance, as reported in recent surveillance studies, do not correspond to current rates of failure in patients with CARTIs. This disconnection between laboratory-determined resistance and clinical outcome has been termed the in vitro-in vivo paradox and several explanations have been offered to explain this phenomenon. Solving the problem of antimicrobial resistance will be multifactorial. Important factors in this effort include the education of healthcare providers, patients and the general healthcare community regarding the hazards of inappropriate antibiotic use, prevention of infections through vaccination, development of accurate, inexpensive and timely point-of-care diagnostic tests to aid in patient assessment, institution of objective treatment guidelines and use of more potent agents, especially those with a focused spectrum of activity, earlier in the treatment of CARTIs as opposed to reserving them as second-line treatment options. Ultimately, the single-most important factor will be the judicious use of antibiotics, as fewer antibiotic prescriptions lead to fewer antimicrobial-resistant bacteria.
- 1 June 2006
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 44 (6) , 2262-2264
Comparison of the BACTEC 9240 and BacT/Alert Blood Culture Systems for Detection of Bacterial Contamination in Platelet Concentrates
The BACTEC 9240 blood culture system with a standard aerobic medium, Plus Aerobic/F, was compared to the BacT/Alert system with a platelet-specific medium, BPA, as a means for detecting bacterial contamination of platelet preparations. One hundred thirteen platelet units seeded with low levels of different bacteria were examined with both systems. In 93 instances, growth was detected first in the BACTEC system; in 12 cases, growth registered first in the BacT/Alert system. Among all comparisons, growth was detected, on average, 1.7 h sooner with the BACTEC system. The differences in length of time to detection were statistically significant.
- 1 June 2006
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 44 (6) , 2262-2264
Comparison of the BACTEC 9240 and BacT/Alert Blood Culture Systems for Detection of Bacterial Contamination in Platelet Concentrates
The BACTEC 9240 blood culture system with a standard aerobic medium, Plus Aerobic/F, was compared to the BacT/Alert system with a platelet-specific medium, BPA, as a means for detecting bacterial contamination of platelet preparations. One hundred thirteen platelet units seeded with low levels of different bacteria were examined with both systems. In 93 instances, growth was detected first in the BACTEC system; in 12 cases, growth registered first in the BacT/Alert system. Among all comparisons, growth was detected, on average, 1.7 h sooner with the BACTEC system. The differences in length of time to detection were statistically significant.
- Open Access
- 15 July 2005
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (2) , 139-148
Antimicrobial Resistance amongStreptococcus pneumoniaein the United States: Have We Begun to Turn the Corner on Resistance to Certain Antimicrobial Classes?
Background. Antimicrobial resistance has emerged as a major problem in Streptococcus pneumoniae in the United States during the past 15 years. This s
- 15 July 2005
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (2) , 139-148
Open AccessAntimicrobial Resistance amongStreptococcus pneumoniaein the United States: Have We Begun to Turn the Corner on Resistance to Certain Antimicrobial Classes?
Background. Antimicrobial resistance has emerged as a major problem in Streptococcus pneumoniae in the United States during the past 15 years. This s